Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for Cocaine Abuse and Adult ADHD
NCT00218543Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Jun 2004
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atomoxetine in cocaine dependence and attention deficit hyperactivity disorder (ADHD), sponsored by New York State Psychiatric Institute. Primary endpoints: Adult ADHD Rating Scale (30% Reduction) at 12 weeks, ADHD Symptoms Based on Adult ADHD Rating Scale at 12 weeks and 1 more. Started Jun 2004; status: completed.
02
Drugs
atomoxetine
03
Conditions
cocaine dependenceattention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00218543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00218543.